# Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cefiderocol-versus-high-dose-extended-infusion-meropenem-for-the-treatment-of/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Richard G. Wunderink,Yuko Matsunaga,Mari Ariyasu,Philippe Clevenbergh,Roger Echols,Keith S. Kaye,Marin H. Kollef,Anju Menon,Jason M. Pogue,Andrew F. Shorr,Jean‐François Timsit,Markus Zeitlinger,Tsutae Den Nagata |
| Citations | 478 |
| DOI | 10.1016/s1473-3099(20)30731-3 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3092173712 |
| PMID | 33058798 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Jean‐François Timsit](https://scholariq.org/researchers/jean-francois-timsit/)

## Paper primary topic

- [Nosocomial Infections in ICU](https://scholariq.org/topics/nosocomial-infections-in-icu/)

## Paper topics

- [Nosocomial Infections in ICU](https://scholariq.org/topics/nosocomial-infections-in-icu/)
- [Antibiotics Pharmacokinetics and Efficacy](https://scholariq.org/topics/antibiotics-pharmacokinetics-and-efficacy/)
- [Antibiotic Resistance in Bacteria](https://scholariq.org/topics/antibiotic-resistance-in-bacteria/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.